Medarex in antibody pact with NovImmune
Medarex of the USA and Switzerland's NovImmune have announced acollaboration to develop fully-human therapeutic antibodies, whereby the former will use its UltiMAb Human Antibody Development System to generate antibodies to disease targets discovered by NovImmune.
Medarex will receive undisclosed license fees and milestone payments as well as royalties on commercial sales from any products resulting from the agreement. Jack Barbut, NovImmune's chief executive, said that the collaboration "will accelerate our drug development process from novel targets to clinical trials." He added that the deal "allows flexibility in the choice of business models, with the possibility of different degrees of involvement by Medarex in the development of our new therapeutic monoclonal antibodies."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze